Lutetium (177Lu) oxodotreotide (INN) or 177Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5] .

Lutetium-177 (Lu-177) PSMA therapy (Pluvicto) is a new theranostic treatment that targets a specific molecule on the surface of prostate cancer cells, effectively killing the cancer cells while preserving healthy tissues.

2024年1月20日 · Mayo Clinic researchers found that lutetium-177 (177 Lu)-PSMA-617 prolonged radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who were taxane-naive and had progressive disease after receiving androgen receptor pathway inhibition (ARPI) therapy compared with …

2021年6月23日 · Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177 Lu)–PSMA-617 is a radioligand therapy that delivers...

What is PLUVICTO ® (lutetium Lu 177 vipivotide tetraxetan)? PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen­–­positive metastatic castration-resistant …

Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

2025年2月1日 · Lutetium Lu 177 dotatate injection is used to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors of the different parts of the gut. Lutetium Lu 177 dotatate injection is a radiopharmaceutical.

On March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment...

2023年1月18日 · Lutetium-177 (Lu-177) is a medical isotope used in targeted radionuclide therapy for treating neuroendocrine tumours and prostate cancer. It is produced in NRG’s nuclear facility and it is currently the most commonly used isotope for targeted radionuclide therapy.

Lutetium Lu 177-dotatate is approved to treat: Gastroenteropancreatic neuroendocrine tumors. It is used in adults and children aged 12 years and older whose cancer is somatostatin receptor positive. Lutetium Lu 177-dotatate is also being studied in the treatment of other types of cancer.